AbbVie price target raised to $214 from $212 at Guggenheim

Guggenheim raised the firm’s price target on AbbVie (ABBV) to $214 from $212 and keeps a Buy rating on the shares after updating its company model following the company’s “strong” Q4 and initial FY25 guidance last Friday morning. The firm continues to like AbbVie shares at current levels given the company’s “solid growth outlook at least through the end of the decade,” the analyst tells investors in a post-earnings note.